

Finely crafted investments

Amati
Global Investors



T. BAILEY

TB Amati Investment Funds

Interim Report and Financial Statements (Unaudited)
31 July 2020

TB Amati UK Smaller Companies Fund

CONTENTS

The Authorised Corporate Director and Investment Manager, Your Investments, Risk Profile. Synthetic Risk and Reward Indicator, Ongoing Charges Figure.....	1 2
Authorised Status, Structure of the Company, Investment Objective and Policy.....	3
Other Information, The Investment Management Team.....	4
Biographies.....	5
Statement of the Authorised Corporate Director's Responsibilities, Director's Statement.....	7
Investment Review.....	8
Portfolio Statement.....	13
Summary of Fund Performance.....	18
Statement of Total Return, Statement of Change in Net Assets Attributable to Shareholders	20
Balance Sheet.....	21
Notes to the Financial Statements.....	22
Distribution Table.....	23
Directory.....	24

Note: The Authorised Corporate Director's Report consists of 'Authorised Status', 'Structure of the Company' and 'Investment Objective and Policy' on page 3, 'Investment Review' as provided by the Investment Manager, on pages 8 to 12 and 'Directory' on page 24.

THE AUTHORISED CORPORATE DIRECTOR AND INVESTMENT MANAGER

The Authorised Corporate Director (the 'ACD') of TB Amati Investment Funds (the 'Company') is T. Bailey Fund Services Limited ('TBFS'). Amati Global Investors Limited is the Investment Manager (the 'Investment Manager') of the Company.

Amati Global Investors Limited and T. Bailey Fund Services Limited are authorised and regulated by the Financial Conduct Authority. Further information about Amati Global Investors Limited and the funds which it manages can be found at www.amatiglobal.com.

YOUR INVESTMENTS

You can buy or sell shares in the Company through your Financial Advisor. Alternatively, you can telephone the dealing line; 0115 988 8275, during normal office hours. Application forms can be requested in writing from the ACD or by calling the Client Services Team on the dealing line. They can also be downloaded from www.tbaileyfs.co.uk/funds/tb-amati-investment-funds.

The Company is eligible for ISA investments/transfers and the shares are available as part of a regular savers scheme.

Prices are published each normal business day on www.tbaileyfs.co.uk/funds/tb-amati-investment-funds.

RISK PROFILE

Smaller companies' securities are often traded less frequently than those of larger companies, this means they may be more difficult to buy and sell. Their prices may also be subject to short term swings.

The value of investments may go down as well as up in response to general market conditions and the performance of the assets held. Investors may not get back the money which they invested.

There is no guarantee that the Fund will meet its stated objectives.

The movements of exchange rates may lead to further changes in the value of investments and the income from them.

There is a risk that any company providing services such as safe keeping of assets or acting as counterparty to derivatives may become insolvent, which may cause losses to the Fund.

SYNTHETIC RISK AND REWARD INDICATOR

The Synthetic Risk and Reward Indicator demonstrates in a standard format where the Fund ranks in terms of its potential risk and reward. It is based on historical performance data, may change over time and may not be a reliable indication of the future risk profile of the Fund. The indicator uses a scale of 1 to 7. The higher the rank the greater the potential reward but the greater the risk of losing money. The lowest category does not mean a fund is a risk free investment.

The Fund is in risk category 6 because it invests in shares.

ONGOING CHARGES FIGURE

The Ongoing Charges Figure ('OCF') provides investors with a clearer picture of the total annual costs in running a Collective Investment Scheme. The OCF consists principally of the Annual Management Charge, but also includes the costs for other services paid in respect of Depositary, custody, FCA and audit fees. The OCF, as calculated in accordance with ESMA guidelines, is disclosed as 'Operating charges (p.a.)' in the Summary of Fund Performance tables on pages 18 and 19.

AUTHORISED STATUS

TB Amati Investment Funds (the 'Company') is an investment company with variable capital incorporated in England and Wales under registered number IC000618 and authorised by the Financial Conduct Authority with effect from 26 March 2008. The Company has an unlimited duration.

Shareholders are not liable for the debts of the Company. Shareholders are not liable to make any further payment to the Company after they have paid the price on purchase of the Shares.

STRUCTURE OF THE COMPANY

The Company is a UCITS scheme.

The Company is structured as an umbrella so that the Scheme Property of the Company may be divided among one or more sub-funds. The assets of each sub-fund will generally be treated as separate from those of every other sub-fund and will be invested in accordance with the investment objective and investment policy applicable to that sub-fund. New sub-funds may be established from time to time by the ACD with the approval of the FCA and the agreement of the Depositary. If a new sub-fund is introduced, a new Prospectus will be prepared to set out the required information in relation to that sub-fund.

The Company is compliant with the Protected Cell Regime for OEICs. Under the Protected Cell Regime, each sub-fund represents a segregated portfolio of assets and, accordingly, the assets of a sub-fund belong exclusively to that sub-fund and shall not be used or made available to discharge (directly or indirectly) the liabilities of, or claims against, any other person or body, including any other sub-fund and shall not be available for any such purpose.

Currently, there is one sub-fund in existence; TB Amati UK Smaller Companies Fund (the 'Fund').

The base currency of the Company is Pound Sterling.

INVESTMENT OBJECTIVE AND POLICY

The TB Amati UK Smaller Companies Fund aims to achieve long-term capital growth over periods of 5 years or longer.

At least 80% of the Fund will typically be invested in shares, equity-related securities or bonds in or issued by UK smaller companies. For these purposes, UK companies are companies incorporated or domiciled in the UK, or companies that are listed* in the UK and have the majority of their economic activity in the UK. Smaller companies are companies which form the bottom 10% of the UK equity market by market capitalisation.

The Fund may also invest (up to 20%) in shares, equity-related securities or bonds in or issued by companies which are not UK smaller companies, money market instruments, cash or near cash. There may be occasions when the Investment Manager chooses to hold large degrees in these asset classes in order to protect returns in certain market conditions (e.g. severe market downturns). Up to 10% of the Fund may be invested in collective investment schemes (which may include those managed or operated by the ACD and its associates).

The Fund is actively managed, taking into account the Investment Manager's views on growth opportunities and prevailing market conditions. Derivatives may be used for Efficient Portfolio Management purposes to reduce risk or cost or to generate additional capital or income.

The benchmark of the Fund is the Numis Smaller Companies Index (plus AIM, excluding Investment Companies) Total Return.

* "Listed" for the purposes of the Fund's Objective and Investment Policy means listed on the Main Market of the London Stock Exchange or quoted on the Alternative Investment Market or Aquis Stock Exchange.

OTHER INFORMATION

Full details of TB Amati Investment Funds are set out in the Prospectus. This document provides investors with extensive information about the Company, including risks and expenses. A copy of the Prospectus is available on request from the ACD, or can be downloaded from www.tbaileyfs.co.uk/funds/tb-amati-investment-funds.

The Key Investor Information document and Supplementary Information document are also available from www.tbaileyfs.co.uk/funds/tb-amati-investment-funds.

THE INVESTMENT MANAGEMENT TEAM

The TB Amati UK Smaller Companies Fund* has been managed by Dr Paul Jourdan since 2000, and co-managed with David Stevenson since 2012 and Anna Macdonald since 2018.** The management team believe that smaller companies are a highly attractive asset class for long-term savers, on the proviso that investors appreciate that historically, relative to larger company funds, the significant additional performance has come with some additional volatility of returns. The management team seek to manage the additional risks involved in small company investing by taking a view on the business cycle and other macro-risks in structuring the portfolio. Individual company investments are chosen on the basis of proprietary company research. Amati Global Investors Limited is a specialist investment manager, solely focused on the universe of UK smaller companies.

The Fund and management team's long-term performance record is award winning, and in 2019 the Fund won Investment Week's UK Smaller Companies Fund Manager of the Year Award. In February 2020, the Fund was awarded a fund rating from Square Mile Research along with an upgrade from Bronze analyst rating to Silver from Morningstar. Other fund ratings include Rayner Spencer Mills, FE Trustnet (4 Crowns), Citywire Group Rating (Platinum). Only around 20-25% of groups in each sector are invited by Citywire to receive a rating, and of those groups selected only 10% receive a platinum rating.

Should you wish to receive monthly fund factsheets and updates on events by email, please contact: info@amatiglobal.com

**Note: The TB Amati UK Smaller Companies Fund (formerly CF Amati UK Smaller Companies Fund) was seeded by the transfer of the First State British Smaller Companies Fund to Capita Fund Managers on 29 July 2008.*

***Note: July 2019 saw the fund management team augmented by the appointment of Dr Gareth Blades as an analyst. Prior to joining Amati Global Investors Limited, Dr Blades worked for the University of Edinburgh building and spinning-out therapeutic, med tech, diagnostic and e-health companies, and also for PharmaVentures in healthcare and corporate finance.*

BIOGRAPHIES

Dr Paul Jourdan – CEO and Fund Manager

Dr Paul Jourdan is an award-winning fund manager, with a strong track record in small cap investment. He co-founded Amati Global Investors Limited (“Amati”) following the management buyout of Noble Fund Managers from Noble Group in January 2010, having joined Noble in 2007 as Head of Equities. His fund management career began in 1998 with Stewart Ivory, where he gained experience in UK market and global equities. In 2000 Stewart Ivory was taken over by First State and Paul became manager of what is now the TB Amati UK Smaller Companies Fund. In early 2005 he launched what became Amati VCT plc and in 2010 commenced the management of Amati VCT 2 plc following the award of the investment management contract to Amati in 2010. In May 2018 Amati VCT plc merged with Amati VCT 2 plc which was then renamed Amati AIM VCT plc. In September 2014 Amati launched the Amati IHT Portfolio Service, which Paul co-manages with David Stevenson and Anna Macdonald. Prior to 1998 Paul worked as a professional violinist, including a four year period with the City of Birmingham Symphony Orchestra. He is CEO of Amati and also a trustee of Clean Trade, a charity registered in England and Wales.



David Stevenson – Director and Fund Manager

David joined Amati in 2012. In 2005, he was a co-founding partner of investment boutique Cartesian Capital, which managed a range of retail and institutional UK equity funds in long only and long/short strategies. Prior to that he was Assistant Director at SVM, where he also managed equity products including the small/midcap, UK Opportunities Fund. David started his career at KPMG where he qualified as a Chartered Accountant. He latterly specialised in corporate finance, before moving into private equity with Dunedin Fund Managers. David has co-managed the TB Amati UK Smaller Companies Fund and the Amati AIM VCT since 2012, and the Amati AIM IHT Portfolio Service since 2014.



BIOGRAPHIES (CONTINUED)

Anna Macdonald - Fund Manager

Anna joined Amati in 2018. She began her career as an analyst and fund manager at Henderson Global Investors in London, where she co-managed the core enhanced UK equity product, the UK Equity Market Neutral hedge fund and researched the media sector. After some time living in Kenya, as head of research for Old Mutual Asset Management, she returned to the UK and worked at Threadneedle Investors in London before moving to Edinburgh. Anna joined Amati in 2018 from Adam & Company, where she led research for the PAM-award winning wealth manager and ran the successful AIM-listed portfolio service. Anna also has experience of managing substantial OEICs, private client and charity portfolios and has been a CFA Charterholder since 2003.



STATEMENT OF THE AUTHORISED CORPORATE DIRECTOR'S RESPONSIBILITIES

The Authorised Corporate Director (the "ACD") of TB Amati Investment Funds (the "Company") is responsible for preparing the Report and the Financial Statements in accordance with the Open-Ended Investment Companies Regulations 2001 ("the OEIC Regulations"), the Financial Conduct Authority's Collective Investment Schemes' Sourcebook ("COLL") and the Company's Instrument of Incorporation. The OEIC Regulations and COLL require the ACD to prepare financial statements for each accounting period which:

- are in accordance with United Kingdom Generally Accepted Accounting Practice ("United Kingdom Accounting Standards and applicable law"), including FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Statement of Recommended Practice: "Financial Statements of UK Authorised Funds" issued by the Investment Association ("IA SORP") in May 2014; and
- give a true and fair view of the financial position of the Company and its sub-fund as at the end of the period and the net revenue or expense and the net capital gains or losses on the property of the Company and its sub-fund for that period.

In preparing the financial statements, the ACD is required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable United Kingdom Accounting Standards and the IA SORP have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Company will continue in operation.

The ACD is responsible for keeping adequate accounting records that disclose with reasonable accuracy at any time the financial position of the Company and enable it to ensure that the financial statements comply with the applicable IA SORP and United Kingdom Accounting Standards and applicable law. The ACD is also responsible for the system of internal controls, for safeguarding the assets of the Company and for taking reasonable steps for the prevention and detection of fraud and other irregularities.

DIRECTOR'S STATEMENT

In accordance with COLL 4.5.8BR, the Report and the Financial Statements were approved by the board of directors of the ACD of the Company and authorised for issue on 23 September 2020. The Directors are of the opinion that it is appropriate to continue to adopt the going concern basis in the preparation of the financial statements as the assets of the Company and its sub-fund consist predominantly of readily realisable securities and accordingly the Company has adequate resources to continue in operational existence for at least the next twelve months from the approval of the financial statements.

Gavin Padbury, Director of Operations
T. Bailey Fund Services Limited
Nottingham, United Kingdom
23 September 2020

Rachel Elliott, Finance Director
T. Bailey Fund Services Limited
Nottingham, United Kingdom
23 September 2020


INVESTMENT REVIEW

Performance

	Cumulative returns for the periods ended 31 July 2020 (%)					
	6 months	1 year	3 years	5 years	10 years	From PJ take on*
A Accumulation Shares	(11.36)	0.13	19.60	79.29	290.10	572.64
B Accumulation Shares	(11.03)	0.89	22.32	86.16	319.11	684.80
Numis Smaller Companies plus AIM (excluding Investment Companies)**	(16.18)	(8.74)	(10.18)	12.71	104.04	176.35
IA UK Smaller Companies Sector**	(16.31)	(5.95)	0.30	30.14	175.01	264.19

Source: Financial Express. Total return, bid to bid. Sterling terms. * Performance since Dr Paul Jourdan take on of the Fund on 31 August 2000. ** Comparator Benchmarks.

Past performance is not a reliable indicator of future results. Investors are reminded that the price of shares and the revenue derived from them is not guaranteed and may go down as well as up.



Performance since Dr Paul Jourdan take-on of fund on 31 August 2000. Performance prior to 29 July 2008 relates to First State British Smaller Companies Fund (see page 3). * TB Amati (B Class & A Class) Fund Total Return ** Comparator Benchmark Index: Numis Smaller Companies (plus AIM, excluding Investment Companies) Total Return. Source: Amati Global Investors Ltd as at 31 July 2020.

Past performance is not a reliable indicator of future results. Investors are reminded that the price of shares and the revenue derived from them is not guaranteed and may go down as well as up.

INVESTMENT REVIEW (CONTINUED)

Market Review

The six month period under review has been dominated by the impact of the COVID-19 pandemic. Within a short timescale the global economy felt the full force of economic shutdowns across most countries, with consequential damage to jobs, consumer spending, capital investment and corporate profitability. The dramatic effect on GDP saw individual economies report recessionary conditions for the first two quarters of the year, despite unprecedented emergency measures involving fiscal and monetary stimulus.

Until mid-February stock markets had broadly sustained their momentum from late 2019, as investors assessed whether the initial outbreak in China, and Asia more generally, could be contained. As evidence emerged from Europe that the situation could become a global pandemic, sentiment collapsed causing a rapid sell-off. Initially this was indiscriminate, with all assets – equities, bonds, property and even gold – being hit as liquidity was sought at almost any price. This environment continued in the UK until mid-March. It was followed by a period of almost frenetic capital raising activity, as investors were approached by companies most impacted by the downturn as well as others seeking funding for investment opportunities. This coincided with a view that these might prove to be the last offerings in the event of a strong economic recovery. Alongside a more general search by investors for bargains within the UK market, it fostered a sharp rebound which continued through to early June. This, however, marked a relative high point, as the remainder of the reporting period saw the rally lose momentum, with investors re-assessing the likely trajectory of a future recovery. The rising incidence of virus cases in countries previously successful in controlling the initial outbreaks, plus a cautious rebound in consumer confidence and spending patterns, indicated that the relaxation of lockdowns did not guarantee a return to normal activity.

Against a backdrop of mid and small cap indices registering declines of more than 20% over the six months, the most notable feature in the period was the significant outperformance of AIM, which fell by only a mid-single digit percentage. A significant proportion of companies listed on AIM remained in favour with investors. This included businesses involved in essential elements of the online economy such as retail, data communications, software, video gaming and cyber security, as well as those leading the research into COVID-19 treatments and vaccines.

Performance Review

The unit price (B Accumulation) of the Fund fell by 11.0% during the period, compared to declines in the Numis Smaller Companies (plus AIM excluding Investment Companies) index of 16.2% and the IA UK Smaller Companies sector of 16.3%. The biggest contributor to performance was **Gear4music**, the online retailer of musical instruments and music equipment, with a share price gain of 89%. This reflected the company's exceptionally strong trading during the UK's lockdown period, as households focused on home entertainment. In addition, Gear4music's growth has seen it take market share from smaller independents operating from the high street. For the quarter to end June, sales grew 80% in the UK, and 55% in Europe and the rest of the world, materially ahead of consensus expectations. With distribution centres in the UK, Sweden and Germany, the company has an e-commerce platform capable of driving sustained growth into the future. Another strong performer was **Oxford Biomedica**, a leading gene and cell therapy company, which gained 36%. In April, it announced it had signed a supply agreement with AstraZeneca to manufacture the adeno based COVID-19 vaccine candidate AZD1222, as part of the consortium led by Oxford University. Early trial results have indicated a robust immune response from the vaccine candidate involving a four-fold increase in antibodies in 95% of participants, and a T-cell response in all participants. In addition, Oxford Biomedica has continued to announce manufacturing and licence agreements for its core LentiVector platform technology. **LoopUp**, the SaaS provider of conference call technology, saw significant growth in revenues as working from home practices during lockdown boosted demand. Following a more than doubling of the share price, the position was sold. A new holding in the period, **Renalytix AI**, also performed strongly. The company has developed an artificial intelligence technology for the diagnosis and clinical management of chronic kidney disease, and a series of positive announcements were issued involving its KidneyIntelX platform. This can be used to risk assess

INVESTMENT REVIEW (CONTINUED)

COVID-19 patients, with studies suggesting around 20% of hospitalised cases develop acute kidney injury. Renalytix AI also announced a joint listing on Nasdaq. The shares more than doubled. **Yourgene Health**, a molecular diagnostics specialist in the field of reproductive health, announced a contract manufacturing agreement with Novacyte for the production of critical components in a key COVID-19 diagnostic test. The shares rose 20%.

Other significant contributors to performance in the period included **GlobalData**, a business data and analytics platform provider, which continues to expand internationally; **MaxCyte**, a developer of cell and gene-editing therapies, which anticipated revenue growth of around 30% in its first half trading; **Dechra Pharmaceuticals**, the veterinary medicine specialist, which announced solid trading; **Softcat**, the IT infrastructure and services supplier, which benefited from increased corporate spending on home working measures; and new holding **Inspects**, a global designer and manufacturer of eyewear frames, which floated successfully during the period.

The major detractors from performance involved stocks exposed to the housing market and construction, where business activity was interrupted by the virus lockdown and investors had ongoing fears about market conditions. This included **OneSavings Bank**, the professional landlord buy-to-let mortgage specialist; **Redrow** and **Countryside Properties**, the volume housebuilders; **Watkin Jones**, the student accommodation and build-to-rent construction specialist; and **Forterra**, the brick manufacturer. In each case trading was impacted by the lockdown period, and the companies moved to conserve cash by stopping dividends. Another area affected was the leisure market, with **The Gym Group**, the discount gym operator, and **Hollywood Bowl**, the bowling alley operator, also underperforming. These sites have been amongst the last to re-open after lockdown, and once again trading has been significantly impacted and dividends interrupted. Other underperformers included oil & gas producers **PetroTal** and **Jadestone Energy**, where commodity price weakness created headwinds; and **Morses Club**, the home collected credit provider, on concerns about the impact of social distancing and repayment risks.

A few of these companies raised further capital during the period to strengthen their financial position, but we only participated in a placing for Countryside Properties. The decision was taken, given poor trading visibility and portfolio risk, to sell positions in Redrow, Watkin Jones, Forterra, The Gym Group and Hollywood Bowl .

Portfolio Activity

New positions were introduced to the portfolio where these represented either strong, cyclical businesses likely to fully participate in any recovery, or companies which have already shown the durability of their trading during lockdown. The fund participated in placings for **Jet2** (formerly Dart Group), the holiday operator, and **Air Partner**, a provider of aircraft charter and aviation health & safety services.

Both businesses have robust franchises and should continue to take market share as air travel recovers. Contra-cyclical exposure was added through gold miners **AEX Gold** and **Centamin**, and financial trading platform **CMC Markets**, all of which are experiencing strong underlying markets. Further healthcare involvement came from specialist social care provider **CareTech**, and also **Synaigen**, a respiratory drug development company, and **Renalytix AI**. Technology exposure was added through computer game developers **Codemasters** and **Frontier Developments**; risk management software provider **Ideagen**; and pan-European specialist private equity manager **Draper Esprit**. Both Frontier Developments and Ideagen are stocks already held within the Amati AIM VCT portfolio. Having exited **Spirent Communications**, the telecoms testing solutions provider, in early February the decision was taken to re-invest based on accelerating global investment in 5G technology as a consequence of the impact of the pandemic. As noted above the fund also participated in the IPO of **Inspects**. Major additions to existing holdings included **Grainger**, the UK's largest listed residential landlord, which raised funds to support its growth in the private rental markets ("PRS"); and **IG Design**, the supplier of giftware and stationery, where the fund participated in a heavily over-subscribed placing in January to finance a US acquisition, and then needed to increase the position.

INVESTMENT REVIEW (CONTINUED)

In addition to the disposals previously mentioned, the fund also exited **Premier Asset Management**, following its merger with Miton; **Ricardo**, due to a deteriorating global automotive market; **4imprint**, on concerns about the discretionary nature of US corporate spending on promotional goods; and **Alpha FX** after a profit warning caused by reduced foreign exchange activity. Small positions in **Block Energy** and **Bonhill** were also sold.

The asset allocations as at the year end date are shown in the table below:

Sector	Asset allocation as at 31 July 2020 (%)	Asset allocation as at 31 January 2020 (%)
Aerospace & Defense	1.5	1.7
Construction & Materials	-	1.6
Electricity	0.5	-
Electronic & Electrical Equipment	5.6	4.6
Financial Services	17.6	18.6
General Retailers	1.9	-
Health Care Equipment & Services	3.7	-
Household Goods & Home Construction	6.3	11.9
Industrial Engineering	0.8	2.0
Infrastructure	-	1.7
Leisure Goods	7.5	5.3
Media	3.2	3.9
Mining	3.8	1.4
Mobile Telecommunications	1.8	1.7
NonLife Insurance	1.7	1.0
Oil & Gas Producers	4.8	4.8
Personal goods	2.1	-
Pharmaceuticals & Biotechnology	12.8	9.5
Real Estate Investment & Services	3.5	3.0
Real Estate Investment Trusts	1.2	0.9
Software & Computer Services	7.3	7.1
Support Services	3.2	7.1
Technology Hardware & Equipment	2.7	1.0
Travel & Leisure	2.3	4.9
Cash and Other	4.2	6.3
Total	100.0	100.0

The full list of holdings as at the year end is shown in the Portfolio Statement on pages 13 to 17.

Outlook

Few of us could ever have imagined the first half of 2020 turning out the way it did, and so making predictions about what happens next feels something of a fool's errand. From an economic point of view the two major events of the first half were lockdowns across the globe, which are highly recessionary and damaging to business, and at the same time massive fiscal and monetary stimulus on a scale not seen since WWII. What unfolds in the second half and beyond will reflect the extent to which these factors unwind.

INVESTMENT REVIEW (CONTINUED)

There is much uncertainty as to the speed with which lockdowns and social distancing measures ease and then disappear altogether. It is critically important to an economic recovery that this process does not take too long. What is clearer is that the massive stimulus packages are not likely to be unwound aggressively, because no politician wants to present the plan of austerity which would be required. The extreme growth in money supply is therefore likely to be inflationary in ways which may well prove uncomfortable after a decade of steady real growth and tightly controlled inflation. It will not become clear to what degree this will be evident until the economic suppression of lockdowns fully ends. A potentially dangerous monetary experiment is being played out. Quantitative Easing (QE) solved many of the problems arising from the Great Financial Crisis, without causing inflation to rise significantly. So why not repeat the process on a much bigger scale to solve the COVID-19 crisis? No-one really knows what the limits are to this, but it looks like we may find out. In the meantime we expect that the divergence between the winning and losing sectors will continue, with the more mature industries and services tending to suffer the most. The Fund carries significant exposure to healthcare and the digital economy, which are areas that should continue to perform well.

Paul Jourdan
CEO and Fund Manager
Amati Global Investors Ltd
Edinburgh, United Kingdom
23 September 2020

David Stevenson
Director and Fund Manager
Amati Global Investors Ltd
Edinburgh, United Kingdom
23 September 2020

Anna Macdonald
Fund Manager
Amati Global Investors Ltd
Edinburgh, United Kingdom
23 September 2020

PORTFOLIO STATEMENTAs at 31 July 2020

Holding or nominal value of positions		Bid market value £	Percentage of total net assets %
Aerospace & Defense (1.5%; 31.01.20 - 1.7%)			
2,075,000	QinetiQ	6,345,350	1.5
		6,345,350	1.5
Electricity (0.5%; 31.01.20 - 0.0%)			
532,666,600	Eqtec	2,130,666	0.5
		2,130,666	0.5
Electronic & Electrical Equipment (5.6%; 31.01.20 - 4.6%)			
1,340,582	DiscoverIE	7,963,057	1.9
108,500	Judges Scientific	5,316,500	1.3
269,476	Oxford Instruments	3,627,147	0.9
171,674	XP Power	6,540,779	1.5
		23,447,483	5.6
Financial Services (17.6%; 31.01.20 - 18.6%)			
4,797,501	Argentex	7,795,939	1.9
1,550,000	CMC Markets	4,967,750	1.2
1,100,000	Draper Esprit	5,786,000	1.4
3,450,000	Equals	983,250	0.2
1,230,313	Integrafin	6,655,993	1.6
645,770	Intermediate Capital	8,692,064	2.1
2,051,907	John Laing	6,057,229	1.4
697,466	Liontrust Asset Management	8,578,832	2.0
1,358,200	Manolete Partners	5,432,800	1.3
4,033,283	Morses Club	1,895,643	0.4
621,000	Mortgage Advice Bureau	3,601,800	0.9
3,899,621	OneSavings Bank	9,195,306	2.2
2,456,959	River & Mercantile	4,275,109	1.0
		73,917,715	17.6

PORTFOLIO STATEMENT (CONTINUED)

As at 31 July 2020

Holding or nominal value of positions	Bid market value £	Percentage of total net assets %
General Retailers (1.9%; 31.01.20 - 0.0%)		
661,310 Jet2	4,275,369	1.0
2,349,348 DFS Furniture	3,533,419	0.9
	7,808,788	1.9
Health Care Equipment & Services (3.7%; 31.01.20 - 0.0%)		
1,310,000 CareTech	5,554,400	1.3
2,394,400 Creo Medical	4,597,248	1.1
964,533 Renalytix AI	5,401,385	1.3
964,533 Verici Dx	26,042	0.0
	15,579,075	3.7
Household Goods & Home Construction (6.3%; 31.01.20 - 11.9%)		
1,989,558 Countryside Properties	5,638,407	1.4
1,060,030 IG Design	5,512,156	1.3
820,522 MJ Gleeson	5,005,184	1.2
1,487,034 RWS	8,951,945	2.1
1,600,000 Springfield Properties	1,280,000	0.3
	26,387,692	6.3
Industrial Engineering (0.8%; 31.01.20 - 2.0%)		
197,695 AB Dynamics	3,341,046	0.8
	3,341,046	0.8
Leisure Goods (7.5%; 31.01.20 - 5.3%)		
1,500,000 Codemasters	5,325,000	1.3
805,200 Focusrite	5,636,400	1.3
224,008 Frontier Developments	4,354,716	1.0
1,759,789 Gear4music	8,622,966	2.1
4,515,081 Sumo	7,765,939	1.8
	31,705,021	7.5

PORTFOLIO STATEMENT (CONTINUED)As at 31 July 2020

Holding or nominal value of positions		Bid market value £	Percentage of total net assets %
Media (3.2%; 31.01.20 - 3.9%)			
500,000	GlobalData	7,500,000	1.8
5,750,000	The Pebble Group	6,037,500	1.4
		13,537,500	3.2
Mining (3.8%; 31.01.20 - 1.4%)			
12,222,222	AEX Gold	5,500,000	1.3
2,865,033	Anglo Pacific	3,386,469	0.8
6,178,081	Base Resources (AUD)	708,109	0.2
4,361,213	Base Resources	414,315	0.1
3,000,000	Centamin	6,096,000	1.4
		16,104,893	3.8
Mobile Telecommunications (1.8%; 31.01.20 - 1.7%)			
472,000	Gamma Communications	7,434,000	1.8
		7,434,000	1.8
Non-Life Insurance (1.7%; 31.01.20 - 1.0%)			
4,725,454	Randall & Quilter Investment	6,993,672	1.7
		6,993,672	1.7
Oil & Gas Producers (4.8%; 31.01.20 - 4.8%)			
5,059,500	Diversified Gas & Oil	4,877,358	1.2
1,446,911	Genel Energy	2,071,977	0.5
11,822,336	Jadestone Energy	7,684,518	1.8
9,316,601	Pantheon Resources	1,919,220	0.4
28,168,065	PetroTal	3,661,848	0.9
1,750,000	PetroTal Warrants	-	0.0
		20,214,921	4.8

PORTFOLIO STATEMENT (CONTINUED)As at 31 July 2020

Holding or nominal value of positions		Bid market value £	Percentage of total net assets %
Personal Goods (2.1%; 31.01.20 - 0.0%)			
4,000,000	Inspecc	8,800,000	2.1
		8,800,000	2.1
Pharmaceuticals & Biotechnology (12.8%; 31.01.20 - 9.5%)			
1,022,847	Amryt EMA CVR*	71,965	0.0
1,022,847	Amryt FDA CVR*	167,921	0.0
2,390,347	Amryt Pharma	4,230,914	1.0
1,022,847	Amryt Revenue CVR*	33,750	0.0
987,349	Clinigen	6,960,810	1.7
308,665	Dechra Pharmaceuticals	8,803,126	2.1
1,634,350	Eco Animal Health	3,922,440	0.9
140,528	Genus	4,772,331	1.1
1,709,728	MaxCyte	4,171,736	1.0
1,225,000	MaxCyte Restricted	2,695,000	0.7
1,094,433	Oxford Biomedica	8,941,518	2.1
2,000,000	Synairgen	4,000,000	1.0
29,681,184	Yourgene Health	5,045,801	1.2
		53,817,312	12.8
Real Estate Investment & Services (3.5%; 31.01.20 - 3.0%)			
2,556,550	CLS	4,990,386	1.2
3,429,759	Grainger	9,912,004	2.3
		14,902,390	3.5
Real Estate Investment Trusts (1.2%; 31.01.20 - 0.9%)			
2,218,808	Londonmetric Property	5,112,134	1.2
		5,112,134	1.2

PORTFOLIO STATEMENT (CONTINUED)

As at 31 July 2020

Holding or nominal value of positions		Bid market value £	Percentage of total net assets %
Software & Computer Services (7.3%; 31.01.20 - 7.1%)			
538,803	FDM	5,005,480	1.2
704,171	GB	4,696,821	1.1
3,000,000	Ideagen	5,190,000	1.2
1,554,823	SDL	7,136,638	1.7
695,065	Softcat	8,757,819	2.1
		30,786,758	7.3
Support Services (3.2%; 31.01.20 - 7.1%)			
5,504,855	Begbies Traynor	5,064,467	1.2
618,165	Electrocomponents	4,055,162	1.0
1,171,500	Restore	4,158,825	1.0
		13,278,454	3.2
Technology Hardware & Equipment (2.7%; 31.01.20 - 1.0%)			
2,492,159	Quixant	2,741,375	0.6
3,148,851	Spirent Communications	8,801,039	2.1
		11,542,414	2.7
Travel & Leisure (2.3%; 31.01.20 - 4.9%)			
5,233,334	Air Partner	4,406,467	1.0
3,329,444	Cake Box	5,260,522	1.3
		9,666,989	2.3
	Portfolio of investments	402,854,273	95.8
	Net other assets	17,769,231	4.2
	Total net assets	420,623,504	100.0

*Unquoted assets. All other holdings are in equities quoted on recognised stock exchanges. 'Infrastructure' sector disinvested since the beginning of the period (31 January 2020: 1.7%). 'Construction & Materials' sector disinvested since the beginning of the period (31 January 2020: 1.6%).

SUMMARY OF FUND PERFORMANCE

A Accumulation Shares	1 Feb 2020 to 31 Jul 2020 (Pence per Share)	1 Feb 2019 to 31 Jan 2020 (Pence per Share)	1 Feb 2018 to 31 Jan 2019 (Pence per Share)	1 Feb 2017 to 31 Jan 2018 (Pence per Share)
Change in net assets per share				
Opening net asset value per share	1098.66	897.84	928.82	703.49
Return before operating charges*	(122.45)	217.04	(14.99)	239.09
Operating charges	(7.80)	(16.22)	(15.99)	(13.76)
Return after operating charges*	(130.25)	200.82	(30.98)	225.33
Distributions	0.00	(3.98)	(1.06)	0.00
Retained distributions on accumulation shares	0.00	3.98	1.06	0.00
Closing net asset value per share	968.41	1098.66	897.84	928.82
* after direct transaction costs of:	0.79	3.51	2.57	3.77
Performance				
Return after charges	(11.86)%	22.37%	(3.34)%	32.03%
Other information				
Closing net asset value	£11,220,430	£13,382,775	£9,489,438	£8,852,906
Closing number of shares	1,158,642	1,218,096	1,056,919	953,136
Operating charges (p.a)	1.67%	1.64%	1.67%	1.64%
Direct transaction costs (p.a)	0.17%	0.36%	0.27%	0.45%
Prices				
Highest published share price	1,121.94	1,131.03	1049.66	946.05
Lowest published share price	674.42	884.35	853.00	710.19

Past performance is not a reliable indicator of future results. Investors are reminded that the price of shares and the revenue derived from them is not guaranteed and may go down as well as up.

SUMMARY OF FUND PERFORMANCE (CONTINUED)

B Accumulation Shares	1 Feb 2020 to 31 Jul 2020	1 Feb 2019 to 31 Jan 2020	1 Feb 2018 to 31 Jan 2019	1 Feb 2017 to 31 Jan 2018
	(Pence per Share)	(Pence per Share)	(Pence per Share)	(Pence per Share)
Change in net assets per share				
Opening net asset value per share	1,293.42	1,049.11	1077.17	809.75
Return before operating charges*	(144.01)	254.67	(17.86)	276.15
Operating charges	(5.05)	(10.36)	(10.20)	(8.73)
Return after operating charges*	(149.06)	244.31	(28.06)	267.42
Distributions	(0.67)	(13.24)	(9.59)	(6.69)
Retained distributions on accumulation shares	0.67	13.24	9.59	6.69
Closing net asset value per share	1,144.36	1,293.42	1,049.11	1,077.17
* after direct transaction costs of:	0.93	4.14	2.99	4.41
Performance				
Return after charges	(11.52)%	23.29%	(2.60)%	33.03%
Other information				
Closing net asset value	£409,403,074	£412,256,891	£206,319,655	£105,309,602
Closing number of shares	35,775,820	31,873,323	19,666,197	9,776,521
Operating charges (p.a.)	0.92%	0.89%	0.92%	0.89%
Direct transaction costs (p.a)	0.17%	0.36%	0.27%	0.45%
Prices				
Highest published share price	1,321.40	1,331.34	1,221.66	1097.02
Lowest published share price	794.77	1033.58	995.98	817.46

Past performance is not a reliable indicator of future results. Investors are reminded that the price of shares and the revenue derived from them is not guaranteed and may go down as well as up.

STATEMENT OF TOTAL RETURNFor the six-month period ended 31 July 2020

	31.07.20	31.07.19
	£	£
Income		
Net capital (losses)/gains	(47,833,870)	18,732,402
Revenue	1,997,792	3,048,757
Expenses	(1,779,997)	(1,243,406)
Interest payable and similar charges	-	(32)
Net revenue before taxation	<u>217,795</u>	<u>1,805,319</u>
Taxation	<u>(23,389)</u>	<u>(51,708)</u>
Net revenue after taxation	<u>194,406</u>	<u>1,753,611</u>
Total (loss)/return before distributions	(47,639,464)	20,486,013
Distributions	(225,568)	(1,792,971)
Change in net assets attributable to shareholders from investment activities	<u>(47,865,032)</u>	<u>18,693,042</u>

Note: All of the Company's and sub-fund's results are derived from continuing operations.

STATEMENT OF CHANGE IN NET ASSETS ATTRIBUTABLE TO SHAREHOLDERSFor the six-month period ended 31 July 2020

	31.07.20	31.07.19
	£	£
Opening net assets attributable to shareholders	425,639,667	215,809,093
<i>Movements due to sales and repurchases of shares:</i>		
Amounts receivable on issue of shares	127,003,581	97,058,906
Amounts payable on cancellation of shares	<u>(84,393,451)</u>	<u>(37,699,438)</u>
	42,610,130	59,359,468
Change in net assets attributable to shareholders from investment activities	(47,865,032)	18,693,042
Retained distributions on accumulation shares	238,739	1,958,887
Closing net assets attributable to shareholders	<u>420,623,504</u>	<u>295,820,490</u>

Note: Section 3.30 of the IA SORP requires comparative figures for the end of the half yearly period of the prior year for the above statement. For interim financial statements this will result in the closing comparative net assets not being equal to the net assets at the start of the current period as these are not consecutive periods.

BALANCE SHEET
As at 31 July 2020

	31.07.20	31.01.20
	£	£
Assets:		
Fixed Assets:		
Investments	402,854,273	398,631,622
Current Assets:		
Debtors	6,111,185	7,024,049
Cash and bank balances	14,827,561	24,745,619
Total assets	<u>423,793,019</u>	<u>430,401,290</u>
Liabilities:		
Creditors:		
Other creditors	3,169,515	4,761,623
Total liabilities	<u>3,169,515</u>	<u>4,761,623</u>
Net assets attributable to shareholders	<u>420,623,504</u>	<u>425,639,667</u>

NOTES TO THE FINANCIAL STATEMENTS

As at 31 July 2020

Accounting policies

The financial statements have been prepared on the basis of the accounting policies set out in the Annual Report and Financial Statements for the year ended 31 January 2020.

The financial statements have been prepared under the historical cost basis, as modified by the revaluation of investments, and in accordance with Financial Reporting Standard 102 (FRS 102) and in accordance with the Statement of Recommended Practice (SORP) for Financial Statements of UK Authorised Funds issued by the Investment Association in May 2014.

As described in the Statement of Authorised Corporate Director's Responsibilities, the ACD continues to adopt the going concern basis in the preparation of the financial statements of the Fund.

DISTRIBUTION TABLEFor the six-month period ended 31 July 2020

Interim Distribution (31 July 2020)

Group 1 - Shares purchased on or prior to 31 January 2020

Group 2 - Shares purchased after 31 January 2020

Shares	Revenue (pence)	Equalisation ¹ (pence)	Accumulated 30.09.20 (pence)	Accumulated 30.09.19 (pence)
A Accumulation				
Group 1	-	-	-	3.0754
Group 2	-	-	-	3.0754
B Accumulation				
Group 1	0.6673	-	0.6673	7.7063
Group 2	0.0834	0.5839	0.6673	7.7063

¹ Equalisation applies only to shares purchased during the distribution period (Group 2 shares). It is the average amount of revenue included in the purchase price of all Group 2 shares and is refunded to holders of these shares as a return of capital. Being capital, it is not liable to income tax but must be deducted from the cost of shares for capital gains tax purposes.

DIRECTORY

The Company

TB Amati Investment Funds
64 St. James's Street
Nottingham
NG1 6FJ

Authorised Corporate Director (ACD)

T. Bailey Fund Services Limited
64 St. James's Street
Nottingham
NG1 6FJ

Tel: 0115 988 8200
Website: www.tbaileyfs.co.uk

Authorised and regulated by the Financial Conduct Authority.

Directors of the ACD

Mr M Hughes
Mr G M J Padbury
Mrs R E Elliott
Mrs H C Stevens (Resigned 30 April 2020)
Mr R J Taylor (Resigned 31 October 2019)
Mrs A E Troup (Non-executive)
Mr A Kerneis (Non-executive)

Investment Manager

Amati Global Investors Limited
8 Coates Crescent
Edinburgh
EH3 7AL

Tel: 0131 503 9100
Email: info@amatiglobal.com
Website: www.amatiglobal.com

Authorised and regulated by the Financial Conduct Authority.

Depository

NatWest Trustee & Depository Services Limited
135 Bishopsgate
London
EC2M 3UR

Authorised and regulated by the Financial Conduct Authority and by the Prudential Regulation Authority.

Registrar and Share Dealing

T. Bailey Fund Services Limited
64 St. James's Street
Nottingham
NG1 6FJ

Tel: 0115 988 8200
Dealing Line: 0115 988 8275
Website: www.tbaileyfs.co.uk

Authorised and regulated by the Financial Conduct Authority.

Auditor

Deloitte LLP
Statutory Auditor
4 Brindleyplace
Birmingham
United Kingdom
B1 2HZ

Registered to carry out audit work by the Institute of Chartered Accountants in England and Wales.

Issued by T. Bailey Fund Services Limited ('TBFS'). TBFS is a Regulated Collective Investment Scheme Manager and is authorised and regulated by the Financial Conduct Authority. Registered in England No: 3720363.